Head & Neck/Thyroid Cancers
Conference Coverage
Enoblituzumab plus pembrolizumab shows promise for select solid tumors
WASHINGTON – Combination enoblituzumab and pembrolizumab showed acceptable safety and encouraging antitumor activity in select patients with B7-H3...
From the Journals
Clinical trial: The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma
Few trials have examined deescalation using surgery alone in intermediate- and early-stage HPV-positive cancer.
New Therapies
Immunotherapy may hold the key to defeating virally associated cancers
Conference Coverage
Monalizumab-cetuximab combo shows promise in advanced head and neck SCC
WASHINGTON – Combined monalizumab + cetuximab is safe and promotes deep, durable responses in recurrent or...
Conference Coverage
Adding pembrolizumab to cisplatin-based CRT shows promise in HPV+ head and neck cancers
Pembrolizumab plus cisplatin-based chemoradiotherapy shows promise for locally advanced, HPV-positive head and neck squamous cell carcinoma.
Conference Coverage
Pembrolizumab extends survival of head and neck cancer
MUNICH – Pembrolizumab was associated with longer overall survival and more durable responses than was cetuximab-based chemotherapy.
Conference Coverage
Worse OS, control of low-risk oropharyngeal cancer with cetuximab
Toxicities were similar, but overall survival and disease control in patients with HPV-positive low-risk cancer was worse with cetuximab versus...
Conference Coverage
ESMO 2018: First look at immunotherapy as first-line treatment for HNSCC
Results of KEYNOTE-048, a study of pembrolizumab for first-line treatment of recurrent or metastatic HNSCC, will be presented at ESMO 2018.
From the Journals
Epacadostat plus pembrolizumab shows promise in advanced solid tumors
Investigational drug epacadostat plus pembrolizumab demonstrated promising antitumor activity and safety in patients with advanced solid tumors....
From the Journals
First combo trial of mTOR/BRAF inhibition shows potential
A combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the BRAF inhibitor vemurafenib appears safe for patients with...